作者
Qing Zhou,Nong Yang,Mingfang Zhao,Dingzhi Huang,Jun Zhao,Yan Yu,Ying Yuan,Longhua Sun,Xiaorong Dong,Tongmei Zhang,Qian Chu,Xingya Li,Xiangjiao Meng,Huijuan Wang,Xiang Wang,Dongde Wu,Sheng Hu,Jinlu Shan,Lian Liu,Meili Sun,Zhiye Zhang,Haibo Zhu,Jingjing Huang,Mengna Huang,Lingge Cheng,Sujie Zhang,Hui Zhou,Yi‐Long Wu
摘要
IBI351 is an irreversible and covalent inhibitor of KRAS G12C. Despite FDA approval of two KRAS G12C inhibitors, there are still significant unmet clinical needs in Chinese patients and ongoing concerns about the optimal dosage. Herein, we presented the phase Ia/Ib study of IBI351 monotherapy in Chinese patients with advanced solid tumors harboring KRAS G12C mutation.